Accès gratuit
Numéro
Med Sci (Paris)
Volume 30, Numéro 5, Mai 2014
Page(s) 532 - 536
Section M/S Revues
DOI https://doi.org/10.1051/medsci/20143005016
Publié en ligne 13 juin 2014
  1. Greiss S, Gartner A. Sirtuin/Sir2 Phylogeny, evolutionary considerations and structural conservation. Mol Cells 2009 ; 28 : 407–415. [CrossRef] [PubMed]
  2. Gilgenkrantz H, Perret C. Le silence parlant de la sirtuine 1 dans la stéatose et le cancer du foie. Med Sci (Paris) 2012 ; 28 : 269–271. [CrossRef] [EDP Sciences] [PubMed]
  3. Guarente L. Sirtuins, aging, and metabolism. Cold Spring Harb Symp Quant Biol 2011 ; 76 : 81–90. [CrossRef] [PubMed]
  4. Kim HS, Vassilopoulos A, Wang RH, et al. SIRT2 maintains genome integrity and suppresses tumorigenesis through regulating APC/C activity. Cancer Cell 2011 ; 20 : 487–499. [CrossRef] [PubMed]
  5. Liu PY, Xu N, Malyukova A, et al. The histone deacetylase SIRT2 stabilizes Myc oncoproteins. Cell Death Differ 2012 ; 20 : 503–514. [CrossRef] [PubMed]
  6. Liu Y, Wang DL, Chen S, et al. Oncogene Ras/phosphatidyl inositol 3-kinase (PI3K) signaling targets histone H3 acetylation at lysine K56. J Biol Chem 2012 ; 287 : 41469–41480. [CrossRef] [PubMed]
  7. Sayd S, Thirant C, El-Habr EA, et al. Sirtuin-2 activity is required for glioma stem cell proliferation arrest but not necrosis induced by resveratrol. Stem Cell Rev 2014 ; 10 : 103–113. [CrossRef] [PubMed]
  8. Wang F, Nguyen M, Qin FX, Tong Q. SIRT2 deacetylates FOXO3a in response to oxidative stress and caloric restriction. Aging Cell 2007 ; 6 : 505–514. [CrossRef] [PubMed]
  9. Brunet A. Bien vieillir : la voie de signalisation insuline-FOXO et la longévité. Med Sci (Paris) 2012 ; 28 : 316–320. [CrossRef] [EDP Sciences] [PubMed]
  10. Parmentier F, Lejeune FX, Neri C. Pathways to decoding the clinical potential of stress response FOXO-interaction networks for Huntington’s disease: of gene prioritization and context dependence. Front Aging Neurosci 2013 ; 5 : 22. [CrossRef] [PubMed]
  11. Hori YS, Kuno A, Hosoda R, Horio Y. Regulation of FOXOs and p53 by SIRT1 modulators under oxidative stress. PLoS One 2013 ; 8 : e73875. [CrossRef] [PubMed]
  12. Liu L, Arun A, Ellis L, et al. Sirtuin 2 (SIRT2) enhances 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced nigrostriatal damage via deacetylating Forkhead box O3a (Foxo3a) and activating Bim. J Biol Chem 2012 ; 287 : 32307–32311. [CrossRef] [PubMed]
  13. Outeiro TF, Kontopoulos E, Altmann SM, et al. Sirtuin 2 Inhibitors rescue α-synuclein-mediated toxicity in models of Parkinson’s disease. Science 2007 ; 317 : 516–519. [CrossRef] [PubMed]
  14. Koob AO, Ubhi K, Paulsson JF, et al. Lovastatin ameliorates alpha-synuclein accumulation and oxidation in transgenic mouse models of alpha-synucleinopathies. Exp Neurol 2010 ; 221 : 267–274. [CrossRef] [PubMed]
  15. Taylor DM, Balabadra U, Xiang Z, et al. A brain-permeable small molecule reduces neuronal cholesterol by inhibiting activity of sirtuin 2 deacetylase. ACS Chem Biol 2011 ; 6 : 540–546. [CrossRef] [PubMed]
  16. Chopra V, Quinti L, Kim J, et al. The sirtuin 2 inhibitor AK-7 is neuroprotective in Huntington’s disease mouse models. Cell Rep 2012 ; 2 : 1492–1497. [CrossRef] [PubMed]
  17. Rasouri S, Lagouge M, Auwerx J. SIRT1/PGC-1 - Un axe neuroprotecteur ? Med Sci (Paris) 2007 ; 23 : 840–844. [CrossRef] [EDP Sciences] [PubMed]
  18. Krishnan J, Danzer C, Simka T, et al. Dietary obesity-associated Hif1α activation in adipocytes restricts fatty acid oxidation and energy expenditure via suppression of the Sirt2-NAD+ system. Genes Dev 2012 ; 26 : 259–270. [CrossRef] [PubMed]
  19. Burnett C, Valentini S, Cabreiro F, et al. Absence of effects of Sir2 overexpression on lifespan in C. elegans and Drosophila. Nature 2011 ; 477 : 482–485. [CrossRef] [PubMed]
  20. Park SH, Zhu Y, Ozden O, et al. SIRT2 is a tumor suppressor that connects aging, acetylome, cell cycle signaling, and carcinogenesis. Transl Cancer Res 2012 ; 1 : 15–21. [PubMed]
  21. Jin YH, Kim YJ, Kim DW, et al. Sirt2 interacts with 14-3-3 beta/gamma and down-regulates the activity of p53. Biochem Biophys Res Commun 2008 ; 368 : 690–695. [CrossRef] [PubMed]
  22. Inoue T, Nakayama Y, Yamada H, et al. SIRT2 downregulation confers resistance to microtubule inhibitors by prolonging chronic mitotic arrest. Cell Cycle 2009 ; 8 : 1279–1291. [CrossRef] [PubMed]
  23. Pilon A. Poüs C. Compartimentation et plasticité du réseau microtubulaire. Med Sci (Paris) 2013 ; 29 : 194–199. [CrossRef] [EDP Sciences] [PubMed]
  24. Voelter-Mahlknecht S, Mahlknecht U. The sirtuins in the pathogenesis of cancer. Clin Epigenetics 2010 ; 1 : 71–83. [CrossRef] [PubMed]
  25. Narayan N, Lee IH, Borenstein R, et al. The NAD-dependent deacetylase SIRT2 is required for programmed necrosis. Nature 2012 ; 492 : 199–204. [CrossRef] [PubMed]
  26. Zuo Q, Wu W, Li X, et al. HDAC6 and SIRT2 promote bladder cancer cell migration and invasion by targeting cortactin. Oncol Rep 2012 ; 27 : 819–824. [PubMed]
  27. Zhang Y, Au Q, Zhang M, et al. Identification of a small molecule SIRT2 inhibitor with selective tumor cytotoxicity. Biochem Biophys Res Commun 2009 ; 386 : 729–733. [CrossRef] [PubMed]
  28. Peck B, Chen CY, Ho KK, et al. SIRT inhibitors induce cell death and p53 acetylation through targeting both SIRT1 and SIRT2. Mol Cancer Ther 2010 ; 9 : 844–855. [CrossRef] [PubMed]
  29. Aggarwal BB, Bhardwaj A, Aggarwal RS, et al. Role of resveratrol in prevention and therapy of cancer: preclinical and clinical studies. Anticancer Res 2004 ; 24(5A) : 2783–2840. [PubMed]
  30. Black JC, Mosley A, Kitada T, et al. The SIRT2 deacetylase regulates autoacetylation of p300. Mol Cell 2008 ; 32 : 449–455. [CrossRef] [PubMed]
  31. Beirowski B, Gustin J, Armour SM, et al. Sir-two-homolog 2 (Sirt2) modulates peripheral myelination through polarity protein Par-3/atypical protein kinase C (aPKC) signaling. Proc Natl Acad Sci USA 2011 ; 108 : E952–E961. [CrossRef]
  32. Jiang W, Wang S, Xiao M, et al. Acetylation regulates gluconeogenesis by promoting PEPCK1 degradation via recruiting the UBR5 ubiquitin ligase. Mol Cell 2011 ; 43 : 33–44. [CrossRef] [PubMed]

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.